Effectiveness and safety of apatinib combined with oxaliplatin and S-1 in advanced gastric cancer
Objective To explore effectiveness and safety of apatinib(AMT)combined with oxaliplatin(L-OHP)and tegafur gimeracil oteracil potassium capsule(S-1)in advanced gastric cancer.Methods Eighty-five patients with advanced gastric cancer admitted from January 2021 to December 2023 were selected for the study.The patients were divided into the control group(n=42,L-OHP+S-1)and the observation group(n=43,AMT on basis of the control group).The short-term clinical control effect,adverse drug reactions,quality of life[the 36-item shot-form health status survey(SF-36)]and serum indexes[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)]were compared between the two groups.Results The short-term clinical control effect(remission rate:30.23%,control rate:72.09%)was significantly better in the observation group than that in the control group(remission rate:11.90%,control rate:47.62%;P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(30.23%vs.35.71%,P＞0.05).After treatment,the SF-36 score in the observation group was higher than that in the control group(P＜0.05),and the levels of serum CEA and CA19-9 were lower than those in the control group(P＜0.05).Conclusion AMT combined with L-OHP and S-1 has good effectiveness and safety in the treatment of advanced gastric cancer.
万方数据
维普
